Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study

Annals of Tropical Medicine and Parasitology
S K Shahid

Abstract

Multidrug-resistant organisms cause late-onset ventilator-associated pneumonia (VAP). In a pilot, randomized and controlled study, the efficacy and safety of cefepime, in late-onset VAP in infants, have now been evaluated in Malaysia. Thirty children aged <1 year with late-onset VAP (i.e. VAP occurring 5 or more days after intubation) were randomized to receive cefepime or, as a control, ceftazidime. The clinical responses and the microbiological clearance of tracheal aspirates were evaluated in each arm. Adverse events, if any, were monitored clinically and by blood tests. Ten of the 15 children given cefepime and five of the 15 given ceftazidime showed a satisfactory clinical response (P<0.1). Cefepime appeared significantly better at clearing polymicrobial infections from tracheal aspirates. There were no fatalities in the cefepime arm but three in ceftazidime (P<0.1). The mean (S.E.) durations of antibiotic use were 9.4 (1.5) days for cefepime and 7.6 (1.0) days for ceftazidime (P>0.05). No serious adverse effects were observed in either arm. In conclusion, in late-onset VAP in infants, cefepime monotherapy appears to be at least as effective and safe as ceftazidime monotherapy, with better microbiological clearance.

References

Sep 1, 1990·The American Review of Respiratory Disease·A TorresR Rodriguez-Roisin
Oct 1, 1990·American Journal of Obstetrics and Gynecology·C P Weiner
Apr 1, 1989·The American Review of Respiratory Disease
May 1, 1985·Antimicrobial Agents and Chemotherapy·P C FuchsC Thornsberry
Sep 1, 1994·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·O C TablanM M McNeil
Mar 20, 1996·JAMA : the Journal of the American Medical Association·J Y FagonC Gibert
Jun 24, 1996·The American Journal of Medicine·W J Holloway, D Palmer
Jun 24, 1996·The American Journal of Medicine·R McCabeS Greene
Sep 1, 1995·The Journal of Antimicrobial Chemotherapy·S M QadriP Domenico
Feb 26, 1998·American Journal of Respiratory and Critical Care Medicine·J L TrouilletC Gibert
Apr 8, 1999·American Journal of Respiratory and Critical Care Medicine·D K HeylandC Brun-Buisson
Jul 21, 2000·American Journal of Respiratory and Critical Care Medicine·M RuizA Maldonaldo
Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
Jul 2, 2002·The American Journal of Psychiatry·Justin Sauer, Robert Howard
Jul 2, 2002·The American Journal of Psychiatry·Russell B Hilliard, Robert L Spitzer
May 10, 2003·American Journal of Respiratory and Critical Care Medicine·Muriel FartoukhChristian Brun-Buisson
Nov 20, 2003·JAMA : the Journal of the American Medical Association·Jean ChastreUNKNOWN PneumA Trial Group
Oct 2, 2004·Stroke; a Journal of Cerebral Circulation·Marie-Germaine Bousser
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Apr 19, 2006·Archives of Dermatology·Iris Zalaudek
Dec 22, 2006·The New England Journal of Medicine·UNKNOWN Canadian Critical Care Trials Group
Jul 28, 1967·Science·P H Abelson
Mar 13, 1964·Science·R A Yarnell
Mar 13, 1964·Science·P E Cloud
Oct 27, 2012·Wiener medizinische Wochenschrift·Gerhart Hitzenberger

❮ Previous
Next ❯

Citations

Nov 3, 2010·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Vani VenkatachalamDouglas F Willson
May 4, 2010·The Journal of Pediatrics·Elisabeth E AddersonJames M Hoffman
Jul 5, 2016·The Lancet Infectious Diseases·Laura FolgoriMike Sharland
Mar 13, 2014·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Douglas F WillsonJ Owen Hendley
Sep 17, 2015·The Pediatric Infectious Disease Journal·Christopher J ArnoldUNKNOWN Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee
Mar 22, 2018·Frontiers in Pediatrics·Saber JanMaria Gutierrez
Nov 3, 2021·The Cochrane Database of Systematic Reviews·Steven Kwasi KorangJanus C Jakobsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.